newsfilter
← Latest News
PR Newswire·

Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data

GH
  • Verana Health & Guardant Health announced a partnership to combine regulatory-grade EHR data with clinicogenomic testing data for biopharmaceutical researchers.
  • The collaboration enables scientists to validate correlations between molecular biomarkers, treatment decisions, & clinical outcomes using real-world data.
  • Specific use cases include refining risk assessment for non-muscle invasive bladder cancer (NMIBC) & optimizing treatment selection for BCG therapy vs. earlier escalation.
  • The combined datasets provide longitudinal serial testing information to optimize drug development & accelerate programs for diverse cancer populations.
  • CEO Sujay Jadhav stated the partnership empowers hypothesis testing to guide targeted therapy development & personalize cancer treatments.
  • CMO Craig Eagle noted the data integration will expedite biomarker-based therapy discovery & make the drug development process more economical.
  • The alliance expands Verana's data breadth into solid tumors including lung, breast, & colorectal cancers with considerable patient overlap.
  • The recent merger of COTA with Verana Health expanded the company's therapeutic footprint across oncology, ophthalmology, urology, & neurology.
  • The combined entity serves 17 of the top 20 global biopharma companies with access to over 95 million patients & over 10 million oncology patients.
  • The joint company represents a top-tier partner for FDA-related organizations with combined regulatory expertise & clinical trial solutions.
  • Researchers can learn more at an April 14 webinar or meet Verana representatives at the American Urological Association (AUA) 2026 Annual Meeting.